Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1988 2
1989 4
1990 2
1991 1
1993 3
1994 4
1995 1
1996 3
1997 6
1998 11
1999 10
2000 26
2001 20
2002 24
2003 25
2004 26
2005 31
2006 45
2007 30
2008 36
2009 30
2010 39
2011 34
2012 48
2013 42
2014 47
2015 23
2016 25
2017 28
2018 40
2019 32
2020 50
2021 59
2022 6
Text availability
Article attribute
Article type
Publication date

Search Results

732 results
Results by year
Filters applied: . Clear all
Page 1
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.
Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Kudo M, Breder V, Merle P, Kaseb AO, Li D, Verret W, Xu DZ, Hernandez S, Liu J, Huang C, Mulla S, Wang Y, Lim HY, Zhu AX, Cheng AL; IMbrave150 Investigators. Finn RS, et al. Among authors: galle pr. N Engl J Med. 2020 May 14;382(20):1894-1905. doi: 10.1056/NEJMoa1915745. N Engl J Med. 2020. PMID: 32402160 Clinical Trial.
Sorafenib in advanced hepatocellular carcinoma.
Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J; SHARP Investigators Study Group. Llovet JM, et al. Among authors: galle pr. N Engl J Med. 2008 Jul 24;359(4):378-90. doi: 10.1056/NEJMoa0708857. N Engl J Med. 2008. PMID: 18650514 Free article. Clinical Trial.
Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference.
Llovet JM, Villanueva A, Marrero JA, Schwartz M, Meyer T, Galle PR, Lencioni R, Greten TF, Kudo M, Mandrekar SJ, Zhu AX, Finn RS, Roberts LR; AASLD Panel of Experts on Trial Design in HCC. Llovet JM, et al. Among authors: galle pr. Hepatology. 2021 Jan;73 Suppl 1:158-191. doi: 10.1002/hep.31327. Epub 2020 Sep 9. Hepatology. 2021. PMID: 32430997 Review. No abstract available.
Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma.
Bridgewater J, Galle PR, Khan SA, Llovet JM, Park JW, Patel T, Pawlik TM, Gores GJ. Bridgewater J, et al. Among authors: galle pr. J Hepatol. 2014 Jun;60(6):1268-89. doi: 10.1016/j.jhep.2014.01.021. Epub 2014 Mar 27. J Hepatol. 2014. PMID: 24681130 Free article. No abstract available.
Simplified criteria for the diagnosis of autoimmune hepatitis.
Hennes EM, Zeniya M, Czaja AJ, Parés A, Dalekos GN, Krawitt EL, Bittencourt PL, Porta G, Boberg KM, Hofer H, Bianchi FB, Shibata M, Schramm C, Eisenmann de Torres B, Galle PR, McFarlane I, Dienes HP, Lohse AW; International Autoimmune Hepatitis Group. Hennes EM, et al. Among authors: galle pr. Hepatology. 2008 Jul;48(1):169-76. doi: 10.1002/hep.22322. Hepatology. 2008. PMID: 18537184
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Zhu AX, Kang YK, Yen CJ, Finn RS, Galle PR, Llovet JM, Assenat E, Brandi G, Pracht M, Lim HY, Rau KM, Motomura K, Ohno I, Merle P, Daniele B, Shin DB, Gerken G, Borg C, Hiriart JB, Okusaka T, Morimoto M, Hsu Y, Abada PB, Kudo M; REACH-2 study investigators. Zhu AX, et al. Among authors: galle pr. Lancet Oncol. 2019 Feb;20(2):282-296. doi: 10.1016/S1470-2045(18)30937-9. Epub 2019 Jan 18. Lancet Oncol. 2019. PMID: 30665869 Clinical Trial.
732 results